Влезте в профила си за пълен достъп до възможностите на Eclipse.
Вход
Каталог "Библиографии"
| Списание
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos, M., Goranova-Marinova, V., al., e. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.,
, .
Dimopoulos, M., Goranova-Marinova, V., al., e. .
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study..
: , .
Dimopoulos, M., Goranova-Marinova, V., al., e. ()
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.,
:
Dimopoulos, M.,
Goranova-Marinova, V., &
al., e.
().
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.. The Lancet Oncology; The Lancet Oncology.